Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Poster Session II - NOVEL TARGET/ EXPERIMENTAL FIDINGS TO CLINICAL TRANSLATION 06.00 - NOVEL TARGET/ EXPERIMENTAL FIDINGS TO CLINICAL TRANSLATION - 06.01 - PATHOPHYSIOLOGY OF STROKE / TRANSLATIONAL MEDICINE P1083 - ESOC25-2127 THROMBOEMBOLIC STROKE ALTERS CLAUDIN-5 ISOFORM EXPRESSION CORRELATING TO INCREASED CEREBRAL INFARCT AND EDEMA AS WELL AS DECREASED NEUROLOGICAL FUNCTION Trevor Wendt 1 , Kajsa Arkelius 1 , Henrik Andersson 1 , Rayna Gonzales 2 , Saema Ansar 1 1 Lund University, Lund, Sweden, 2 University of Arizona College of Medicine - Phoenix, Phoenix, United States Background and Aims: Claudin-5, coined as the gatekeeper of neurological function, is integral in the maintenance of the blood-brain barrier (BBB)
By activating both incretin pathways, tirzepatide enhances insulin secretion in a glucose-dependent manner, suppresses glucagon release, delays gastric emptying, and reduces appetite through central nervous system effects
Ingredient amounts, added vitamins, and preparation methods can vary widely across providers
Mass spectrometry Mass analysis can assess whether the principal peptide is consistent with the expected BPC-157 molecular identity
These ideas rely on data drawn from other studies
Patients are generally recommended 4 treatments spread over 2 weeks, but sometimes this can vary, based on the individuals needs
